Sensyne Health PLC Sensyne Health Provides Strategic Update (5937F)
July 19 2021 - 1:00AM
UK Regulatory
TIDMSENS
RNS Number : 5937F
Sensyne Health PLC
19 July 2021
Sensyne Health Provides Strategic Update Including Exploring a
Potential Dual-Listing on Nasdaq
Oxford, U.K. 19 July 2021: Sensyne Health plc (LSE: SENS)
("Sensyne" or the "Company"), the ethical AI company, announces an
update on its strategy which now includes exploring a potential
dual-listing on Nasdaq amongst other options. As stated in our
financial year end trading update on 27 May 2021, the Company
continues to explore strategic opportunities, including making
acquisitions, that leverage its organic growth and create
additional shareholder value. Any decision to list in the US would
complement the Company's primary listing on the AIM market of the
London Stock Exchange and Sensyne remains committed to being a
UK-headquartered company. Any acquisition or strategic equity
partnership would be consistent with Sensyne's commitment to the
ethical application of AI to patient data and its established
strategic research agreements with the NHS and US health
systems.
Lord (Paul) Drayson PhD FREng, Founder & CEO, commented:
"Now is the time for Sensyne to build on the success of its unique
business model that has already created one of the world's fastest
growing patient data resources for life-sciences research. Our
model provides a clear competitive advantage in terms of our
commitment to patient data privacy, our close and collaborative
research with our partners and our fair and transparent financial
arrangements where we share the wealth that we create with the
health systems that work with us. Our double bottom line approach
to business will ensure that Sensyne becomes the leading company in
its field and today's announcement signals our clear commitment to
that goal."
The Company's strategy remains centred on the ethical use of
real-world patient data to support advances in medical and life
science research for the benefit of patients. Sensyne has recently
signed two strategic research agreements ("SRAs") with leading US
health systems, St. Luke's University Health Network in
Pennsylvania and the Colorado Center for Personalized Medicine.
Both SRAs build on the rapidly growing datasets accessed through
ten SRAs signed to date with NHS Trusts, accelerating Sensyne's
strategy to be a global leader in clinical AI with one of the
largest sets of de-identified and anonymised real-world patient
data, including longitudinal phenotypic and genomic data needed for
life sciences research and development.
Sensyne now has access to a total of approximately 18.2 million
unique patient records (approximately 8.4 million in the UK and
approximately 9.8 million in the US) representing more than a 600%
increase in size since September 2020. The Company aims to build an
ethically sourced real-world dataset of approximately 100 million
patient records by the end of 2024.
Sensyne pursues a "double bottom line" business model that
includes working in partnership with healthcare providers such as
the NHS and US health systems to provide a financial return to
partner healthcare systems through equity ownership in the Company
and a share of revenues generated by the Company as it delivers
public health benefits and accelerates the discovery and
development of new medicines.
-ENDS-
For more information please contact:
Sensyne Health ( www.sensynehealth.com ) +44 (0) 330 0581845
Lord (Paul) Drayson PhD FREng FMedSci, Chief Executive
Officer
Dr Richard Pye, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Joint Broker) + 44 (0) 20 7418900
Dr Christopher Golden
James Steel
Oliver Jackson
Liberum (Joint Broker) + 44 (0) 201002000
Bidhi Bhoma
Euan Brown
Consilium Strategic Communications +44 (0) 7780600290
Mary-Jane Elliott
Jessica Hodgson
Davide Salvi
sensynehealth@consilium-comms.com
Stern Investor Relations
(212) 362-1200
Julie Seidel
Julie.seidel@sternir.com
About Sensyne Health
Sensyne Health plc is a clinical AI company that works in
partnership with global healthcare organisations to improve patient
care and accelerate the discovery and development of new medicines.
Sensyne Health is listed on the AIM Market of the London Stock
Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDGPUQUMUPGPPR
(END) Dow Jones Newswires
July 19, 2021 02:00 ET (06:00 GMT)
Sensyne Health (LSE:SENS)
Historical Stock Chart
From Apr 2024 to May 2024
Sensyne Health (LSE:SENS)
Historical Stock Chart
From May 2023 to May 2024